Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Phase II Study of Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07601737 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.

NCT NCT07601737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07601737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Phase II Study of Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Lead sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
April 20, 2026
Completion date
April 30, 2030
Enrollment
182 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head & neck cancer, head and neck squamous cell carcinoma, head and neck squamous cell carcinoma (hnscc), neoadjuvant therapy